BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Promising Insomnia Pill From Merck & Co., Inc. (MRK) Remains "Critical" to Future Amid Recent Setbacks


2/11/2013 7:40:54 AM

The disappointing earnings report Merck recently announced could have prompted restless nights among investors and analysts. The pharmaceutical manufacturer predicted smaller profits for 2013, and said another setback in its drug pipeline and a significant revenue drop from a popular allergy medication that lost patent protection. Now, the Whitehouse Station-based drugmaker is hoping its new insomnia medication, which is under federal review but has shown promising results in clinical trials, may make everyone sleep a little easier. Analysts say it is a critical piece to the company getting back on track. According to Merck, late-stage trials of the drug, Suvorexant, showed it improved a person’s ability to fall asleep and stay asleep, made them less drowsy the next day and had no significant withdrawal symptoms. Suvorexant was filed with the Food and Drug Administration for review in November — the Drug Enforcement Administration will also review it — and a decision is expected in the fall. It was also filed with regulators in Japan. During a question-and-answer session with analysts following the earnings report on Feb. 1, Merck’s president of global human health, Adam Schechter, cited statistics showing 30 percent of the population has sleep issues and 30 percent are chronically treated. Suvorexant "could really have a significant impact and be an important product for these many patients that are suffering from the inability to sleep," he said. With the company’s recent string of otherwise disappointing news, Suvorexant has taken on greater importance at Merck, said Damien Conover, director of pharmaceutical research for MorningStar Research. He noted the world’s third-largest drugmaker had delayed submitting for review its highly touted osteoporosis medicine, Odanacatib; suspended worldwide sales of its cholesterol medicine, Tredaptive; and saw a $480 million decline in revenue last quarter from its top-selling allergy treatment, Singulair, which lost patent protection in August.

Read at nj.com

nj.com
   
Insomnia

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES